1. Home
  2. REGN vs SPOT Comparison

REGN vs SPOT Comparison

Compare REGN & SPOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • SPOT
  • Stock Information
  • Founded
  • REGN 1988
  • SPOT 2006
  • Country
  • REGN United States
  • SPOT Luxembourg
  • Employees
  • REGN N/A
  • SPOT N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • SPOT Broadcasting
  • Sector
  • REGN Health Care
  • SPOT Consumer Discretionary
  • Exchange
  • REGN Nasdaq
  • SPOT Nasdaq
  • Market Cap
  • REGN 110.0B
  • SPOT 95.1B
  • IPO Year
  • REGN 1991
  • SPOT 2018
  • Fundamental
  • Price
  • REGN $681.58
  • SPOT $485.37
  • Analyst Decision
  • REGN Buy
  • SPOT Buy
  • Analyst Count
  • REGN 25
  • SPOT 30
  • Target Price
  • REGN $1,024.28
  • SPOT $443.59
  • AVG Volume (30 Days)
  • REGN 857.0K
  • SPOT 1.6M
  • Earning Date
  • REGN 02-04-2025
  • SPOT 02-04-2025
  • Dividend Yield
  • REGN N/A
  • SPOT N/A
  • EPS Growth
  • REGN 15.31
  • SPOT N/A
  • EPS
  • REGN 40.43
  • SPOT 3.84
  • Revenue
  • REGN $13,847,100,000.00
  • SPOT $16,843,631,490.00
  • Revenue This Year
  • REGN $10.24
  • SPOT $20.17
  • Revenue Next Year
  • REGN $4.30
  • SPOT $14.84
  • P/E Ratio
  • REGN $16.86
  • SPOT $126.33
  • Revenue Growth
  • REGN 5.72
  • SPOT 18.52
  • 52 Week Low
  • REGN $666.25
  • SPOT $202.30
  • 52 Week High
  • REGN $1,211.20
  • SPOT $506.47
  • Technical
  • Relative Strength Index (RSI)
  • REGN 36.27
  • SPOT 57.47
  • Support Level
  • REGN $666.25
  • SPOT $451.43
  • Resistance Level
  • REGN $743.28
  • SPOT $500.48
  • Average True Range (ATR)
  • REGN 19.76
  • SPOT 13.75
  • MACD
  • REGN 0.45
  • SPOT 2.18
  • Stochastic Oscillator
  • REGN 19.90
  • SPOT 69.48

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

About SPOT Spotify Technology S.A.

Spotify is the leading global music streaming service provider, with over 600 million monthly active users and 250 million paying subscribers, with the latter comprising the firm's premium segment. most of the firm's revenue and nearly all its gross profit come from the subscribers, who pay a monthly fee to access a very comprehensive music library that consists of most of the most popular songs ever recorded, including all from the major record labels. The firm also sells separate audiobook subscriptions and integrates podcasts within its standard music app. Podcast content is not exclusive and is typically free to access on other platforms. Ad-supported users can access a similar music catalog but cannot customize a similar on-demand experience.

Share on Social Networks: